| Objective:Chronic myelogenous leukemia(CML)is a malignant hematological disease,belonging to bone marrow proliferative tumor,accounting for 15%～20% of adult leukemia.The annual incidence rate of CML is 1/100000,and the incidence rate increases with age.The Peak incidence age is 50～60 years old,and the ratio of male to female is 1.4:1 [1].Its Pathogenesis is that the translocation of ABL gene on chromosome 9 and BCR gene on chromosome 22 produces philadelphia chromosome(Ph chromosome),that is,t(9;22)(q34;q11).This chromosome forms BCR-ABL fusion gene at the molecular level.This gene causes abnormal activation of tyrosine kinase and forms P210 protein through downstream signal Pathway,resulting in abnormal cell Proliferation,apoptosis inhibition,and ultimately malignant transformation of cells,Cause the occurrence of leukemia.Although the field of CML targeted therapy has made rapid Progress,there are still many Problems to be solved.CML stem cells cannot be cleared by standard TKIs,the treatment of advanced Patients is still not ideal,drug resistance is widespread,and the source of HSCT is insufficient.In addition to the application and improvement of existing treatment methods,new treatment models and more targeted small molecular drugs need to be researched and developed.Tumor immunotherapy uses the anti-tumor immune system to destroy cancer cells.Among the multiple functions of anti-tumor immunity,immune checkpoints have gradually attracted theattention of researchers,and a large amount of evidence shows their importance.The immune checkpoint of herpes virus entry medium(HVEM)may be a Prognostic marker related to OS,and may be the target of immune checkpoint blocking therapy.One of its ligands,LIGHT,also known as tumor necrosis factor superfamily member 14(TNFSF14)or CD258,can improve the immunotherapeutic effect of a variety of cancer models,such as lung cancer,breast cancer,cervical cancer,Prostate cancer and glioblastoma multiforme.In view of the important regulatory and anti-tumor effects of LIGHT/TNFSF14 on the body immunity,and no literature has reported its effect on the Progression of chronic myeloid leukemia.Therefore,by studying the concentration of LIGHT in Patients with chronic myeloid leukemia and healthy people,this paper discusses the Possible role of LIGHT in the disease and its relationship with T lymphocyte subsets.The expected resultsare expected to Providetheoretical data and Prerequisitesupport for clinical treatment to find newtargets,curativeeffects and Prognosis.Methods:54 Patients with chronic myeloid leukemia admitted to the First Affiliated Hos Pital of Gannan Medical College from July 2021 to December 2022 were selected as the experimental group,and 50 healthy Persons matched with the age and sex of the Patients were selected as the control group.According to the transcription level of BCR-ABLIS(%)after treatment,the test group was divided into 11 Patients in the initial diagnosis group(BCR-ABLIS ≥ 10%),5Patients in the Pre-MMR group(BCR-ABLIS ≥ 0.1%),12 Patients in the MMR group(BCR-ABLIS<0.1%),and 26 Patients in the DMR group(BCR-ABLIS<0.0032%).The concentration of LIGHT in the serum of the two groups was detected by enzyme-linked immunosorbent assay(ELISA);The results of T-cell lymphoid subgroup count were detected byflow cytometry and compared statistically.Results:The serum LIGHT concentration [180.5(99.3280.1)pg/ml] in the test group was lower than the median light concentration(P25,P75)in the control group(267.9(177.3341.0)pg/ml,P=0.001 < 0.05),the difference was statistically significant,and the serum LIGHT concentration in the test group was lower than that in the control group.The median serum LIGHT factor concentration(P25,P75)was 62.3(34.2,85.3)pg/ml in the newly diagnosed group,173.8(152.7190.6)pg/ml in the Pre-MMR group,169.4(77.1275.6)pg/ml in the MMR group,and 234.6(183.2337.3)pg/ml in the DMR group.compared with Pre-MMR group(P=0.009),MMR group(P=0.018),DMR group(P<0.001)and control group(P<0.001),the P value of the initial diagnosis group is less than 0.05,and the difference is statistically significant.It can be considered that the light concentration of the initial diagnosis group is different from other groups and lower than other groups;compared with the MMR group(P=0.625>0.05),the DMR group(P=0.08>0.05)and the control group(P=0.046<0.05),the difference between the Pre-MMR group and the MMR group and the DMR group was not statistically significant,but the difference between the Pre-MMR group and the control group was statistically significant.It can be considered that the light concentration of the Pre-MMR group was different from the control group,and the light concentration of the Pre-MMR group was lower than the control group.compared with DMR group,the concentration of LIGHT in MMR group had no significant difference(P=0.88>0.05);The light concentration in MMR group was significantly lowerthan that incontrol group(P=0.035 < 0.05),and thelight concentration in MMR group was lower than that in control group.compared with the control group,the concentration of LIGHT in DMR group was 0.738>0.05,and the difference was not statistically significant.The correlation coefficient between LIGHT concentration and CD3+T cell count was0.543,P<0.001,and there was a Positive correlation between them;The correlation coefficient between LIGHT concentration and CD3+CD8+T cell count was 0.369,P<0.001,and there was a positive correlation between the two;The correlation coefficient between LIGHT concentration and CD3+CD4+T cell count was 0.569,P<0.001,and there was a Positive correlation between thetwo.Conclusion:The level of LIGHT in Patients with chronic myeloid leukemia is lower than that in healthy people.With the gradual increase of LIGHT level after treatment,there is no significant difference between the level of LIGHT and that of healthy people when the treatment reaches deep molecular biological remission.T cell lymphoid subgroup was correlated with LIGHT expression;The level of LIGHT can be used as a clinical therapeutic evaluation index for chronic myeloid leukemia,and may have some value for the Prognosis of chronic myeloid leukemia Patients,but it still needs a lot of dataresearch to Prove. |
PDF Full Text Request